Why the study?
How should antiplatelet and anticoagulant drugs be managed in patients undergoing elective ophthalmic surgery?
How should antiplatelet and anticoagulant drugs be managed in patients undergoing elective ophthalmic surgery?
Provides updated multidisciplinary guidance for managing antiplatelet and anticoagulant therapies during elective ophthalmic surgery to minimize bleeding and thrombotic risks.
Guides safe perioperative antithrombotic management in ophthalmic surgery; extends prior recommendations to include newer UK agents.
The management of antiplatelet and anticoagulant treatment can be challenging for the ophthalmic surgeon with the risk of impaired surgical view or potentially sight-threatening haemorrhage. With the advent of newer medications and the expanding usage of these drugs, there is a need for up-to-date guidance on the subject. This paper describes the current use of modern antiplatelet and anticoagulant drugs in the UK, and reviews the evidence of such treatments in the context of ophthalmic surgery. A multidisciplinary approach has been used to develop a guideline for the management of antiplatelet and anticoagulation treatment in elective ophthalmic surgery. Specifically, guidance is provided on when and how to stop antiplatelet and anticoagulant treatment and, importantly, when to seek specialist medical advice.
No takes yet. Share an insight, caveat, or question.
Kiire et al. (2014) conducted a review in Patients undergoing elective ophthalmic surgery on antiplatelet and anticoagulant drugs. Management of antiplatelet and anticoagulant drugs was evaluated. A multidisciplinary guideline was developed to provide recommendations on when and how to stop antiplatelet and anticoagulant treatment in patients undergoing elective ophthalmic surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: